Faculty Opinions recommendation of Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

2012 ◽  
Author(s):  
Gwo-Tzer Ho
Keyword(s):  
Monoclonal Antibody ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

Gut ◽  
2012 ◽  
Vol 61 (12) ◽  
pp. 1693-1700 ◽  
Author(s):  
Wolfgang Hueber ◽  
Bruce E Sands ◽  
Steve Lewitzky ◽  
Marc Vandemeulebroecke ◽  
Walter Reinisch ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Tu1716 – Highly Bioavailable Curcumin (Theracurmin®) for Crohn's Disease: Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial

2019 ◽  
Vol 156 (6) ◽  
pp. S-1096 ◽  
Author(s):  
Ken Sugimoto ◽  
Kentaro Ikeya ◽  
Shigeki Bamba ◽  
Akira Andoh ◽  
Hiroshi Yamasaki ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Double blind, placebo controlled trial of metronidazole in Crohn's disease.

Gut ◽  
1991 ◽  
Vol 32 (9) ◽  
pp. 1071-1075 ◽  
Author(s):  
L Sutherland ◽  
J Singleton ◽  
J Sessions ◽  
S Hanauer ◽  
E Krawitt ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document